Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity

Journal of Crohn's and Colitis

Volumn 7, Issue 6, 2013, Pages 481-489

  Pearl, Daniel S ^a   Shah, Krina ^b   Whittaker, Mark A ^c   Nitch Smith, Harriet ^c   Brown, James F ^b   Shute, Janis K ^b   Trebble, Timothy M ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Colitis; ; Interferon gamma; Interleukin 8; ; Transforming growth factor beta; ; Tumour necrosis factor alpha; ; Ulcerative;

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 8; MERCAPTOPURINE; METHOTREXATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LAMINA PROPRIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUESTIONNAIRE; SIGMOIDOSCOPY; ULCERATIVE COLITIS;

ADULT; BIOPSY; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84877080047     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.07.022     Document Type: Article

References (42)

1. Stonnington C.M., Phillips S.F., Melton L.J., Zinsmeister A.R. Chronic ulcerative colitis: incidence and prevalence in a community. Gut 1987, 28:402-409.
2. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
3. Geboes K., Riddell R., Ost A., Jensfelt B., Persson T., Lofberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47:404-409.
4. Geboes J.K. Histopathology of Crohn's disease and ulcerative colitis. Inflammatory Bowel Disease 2003, 255-276. Churchill Livingstone, Edinburgh, London, Melbourne. J. Satsangi, L.R. Sutherland, J.F. Colombel, C. Fiocci, R. Lofberg, J. Pemberton, P. Rutgeerts (Eds.).
5. Ochsenkuhn T., D'Haens G. Current misunderstandings in the management of ulcerative colitis. Gut 2011, 60:1294-1299.
6. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
7. Huang X., Lv B., Jin H.F., Zhang S. A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis. Eur J Clin Pharmacol 2011, 67:759-766.
8. Filippi J., Allen P.B., Hebuterne X., Peyrin-Biroulet L. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011.
9. Fuss I.J., Heller F., Boirivant M., Leon F., Yoshida M., Fichtner-Feigl S., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004, 113:1490-1497.
10. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
11. Masuda H., Iwai S., Tanaka T., Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995, 46:111-123.
12. Inoue S., Matsumoto T., Iida M., Mizuno M., Kuroki F., Hoshika K., et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 1999, 94:2441-2446.
13. Coombes J.L., Maloy K.J. Control of intestinal homeostasis by regulatory T cells and dendritic cells. Semin Immunol 2007, 19:116-126.
14. Yaqoob P., Newsholme E.A., Calder P.C. Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells. Cytokine 1999, 11:600-605.
15. Gomes P., du B.C., Smith C.L., Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986, 27:92-95.
16. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
17. Sutherland L.R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
18. Andus T., Daig R., Vogl D., Aschenbrenner E., Lock G., Hollerbach S., et al. Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut 1997, 41:651-657.
19. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989, 84:1045-1049.
20. Carty E., De B.M., Feakins R.M., Rampton D.S. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000, 46:487-492.
21. Daig R., Andus T., Aschenbrenner E., Falk W., Scholmerich J., Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996, 38:216-222.
22. Ina K., Kusugami K., Yamaguchi T., Imada A., Hosokawa T., Ohsuga M., et al. Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol 1997, 92:1342-1346.
23. Matsuda R., Koide T., Tokoro C., Yamamoto T., Godai T., Morohashi T., et al. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009, 15:328-334.
24. Mazzucchelli L., Hauser C., Zgraggen K., Wagner H., Hess M., Laissue J.A., et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol 1994, 144:997-1007.
25. Geboes K. What histologic features best differentiate Crohn's disease from ulcerative colitis?. Inflamm Bowel Dis 2008, 14(Suppl. 2):S168-S169.
26. Yamamoto T., Umegae S., Kitagawa T., Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis 2005, 11:589-596.
27. Gorelik L., Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002, 2:46-53.
28. Ohtsuka Y., Sanderson I.R. Transforming growth factor-beta: an important cytokine in the mucosal immune response. Curr Opin Gastroenterol 2000, 16:541-545.
29. Ghiringhelli F., Menard C., Terme M., Flament C., Taieb J., Chaput N., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005, 202:1075-1085.
30. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.
31. Satoh Y., Ishiguro Y., Sakuraba H., Kawaguchi S., Hiraga H., Fukuda S., et al. Cyclosporine regulates intestinal epithelial apoptosis via TGF-beta-related signaling. Am J Physiol Gastrointest Liver Physiol 2009, 297:G514-G519.
32. Beck P.L., Rosenberg I.M., Xavier R.J., Koh T., Wong J.F., Podolsky D.K. Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am J Pathol 2003, 162:597-608.
33. Hahm K.B., Im Y.H., Parks T.W., Park S.H., Markowitz S., Jung H.Y., et al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001, 49:190-198.
34. Wuyts W.A., Vanaudenaerde B.M., Dupont L.J., Van Raemdonck D.E., Demedts M.G., Verleden G.M. Interleukin-17-induced interleukin-8 release in human airway smooth muscle cells: role for mitogen-activated kinases and nuclear factor-kappaB. J Heart Lung Transplant 2005, 24:875-881.
35. Lee J.W., Wang P., Kattah M.G., Youssef S., Steinman L., DeFea K., et al. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol 2008, 181:6536-6545.
36. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
37. Shih D.Q., Targan S.R. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008, 14:390-400.
38. Karttunnen R., Breese E.J., Walker-Smith J.A., MacDonald T.T. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol 1994, 47:1015-1018.
39. MacDonald T.T., Hutchings P., Choy M.Y., Murch S., Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990, 81:301-305.
40. Reimund J.M., Wittersheim C., Dumont S., Muller C.D., Baumann R., Poindron P., et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996, 16:144-150.
41. Wang Y.D., Mao J.W. Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis. World J Gastroenterol 2007, 13:5926-5932.
42. Balding J., Livingstone W.J., Conroy J., Mynett-Johnson L., Weir D.G., Mahmud N., et al. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm 2004, 13:181-187.